Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial - Bruix, J; Qin, S; Merle, P (Lancet, 2017)
(10064):